The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo

BRAF 假基因作为竞争性内源性 RNA 发挥作用,并在体内诱发淋巴瘤

阅读:8
作者:Florian A Karreth, Markus Reschke, Anna Ruocco, Christopher Ng, Bjoern Chapuy, Valentine Léopold, Marcela Sjoberg, Thomas M Keane, Akanksha Verma, Ugo Ala, Yvonne Tay, David Wu, Nina Seitzer, Martin Del Castillo Velasco-Herrera, Anne Bothmer, Jacqueline Fung, Fernanda Langellotto, Scott J Rodig, Oli

Abstract

Research over the past decade has suggested important roles for pseudogenes in physiology and disease. In vitro experiments demonstrated that pseudogenes contribute to cell transformation through several mechanisms. However, in vivo evidence for a causal role of pseudogenes in cancer development is lacking. Here, we report that mice engineered to overexpress either the full-length murine B-Raf pseudogene Braf-rs1 or its pseudo "CDS" or "3' UTR" develop an aggressive malignancy resembling human diffuse large B cell lymphoma. We show that Braf-rs1 and its human ortholog, BRAFP1, elicit their oncogenic activity, at least in part, as competitive endogenous RNAs (ceRNAs) that elevate BRAF expression and MAPK activation in vitro and in vivo. Notably, we find that transcriptional or genomic aberrations of BRAFP1 occur frequently in multiple human cancers, including B cell lymphomas. Our engineered mouse models demonstrate the oncogenic potential of pseudogenes and indicate that ceRNA-mediated microRNA sequestration may contribute to the development of cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。